Abstract
Heart failure, a major symptom in the progression of cardiac hypertrophy, is a critical risk factor for cardiac death. A large body of research has investigated cardioprotective mechanisms that prevent or minimize hypertrophy, identifying a variety of specific peptide hormones, growth factors, and cytokines with cardioprotective properties. Recent investigation of the downstream effector pathways for these growth factors has identified molecules involved in the progression of cardiac hypertrophy and heart failure, including phosphoinositide 3-kinase (PI3K), Akt and mammalian target of rapamycin (mTOR). Using genetically modified transgenic or knockout mice and adenoviral targeting to manipulate expression or function in experimental models of heart failure, several investigators have demonstrated that the PI3K-Akt pathway regulates cardiomyocyte size, survival, angiogenesis, and inflammation in both physiological and pathological cardiac hypertrophy. In this review, we discuss the reciprocal regulation of PI3K, Akt and mTOR in cardiomyocytes and their association with cardiac disease.
Keywords: PI3K, Akt, mTOR, cardiac hypertrophy, heart failure, hypertrophy, reciprocal, cardiomyocytes, phosphoinositide, cardioprotective, rapamycin, heterodimers, tensin, hormones, fibrosis, phosphotyrosine, manganese
Current Pharmaceutical Design
Title: Phosphoinositide-3 Kinase Signaling in Cardiac Hypertrophy and Heart Failure
Volume: 17 Issue: 18
Author(s): Toshinori Aoyagi and Takashi Matsui
Affiliation:
Keywords: PI3K, Akt, mTOR, cardiac hypertrophy, heart failure, hypertrophy, reciprocal, cardiomyocytes, phosphoinositide, cardioprotective, rapamycin, heterodimers, tensin, hormones, fibrosis, phosphotyrosine, manganese
Abstract: Heart failure, a major symptom in the progression of cardiac hypertrophy, is a critical risk factor for cardiac death. A large body of research has investigated cardioprotective mechanisms that prevent or minimize hypertrophy, identifying a variety of specific peptide hormones, growth factors, and cytokines with cardioprotective properties. Recent investigation of the downstream effector pathways for these growth factors has identified molecules involved in the progression of cardiac hypertrophy and heart failure, including phosphoinositide 3-kinase (PI3K), Akt and mammalian target of rapamycin (mTOR). Using genetically modified transgenic or knockout mice and adenoviral targeting to manipulate expression or function in experimental models of heart failure, several investigators have demonstrated that the PI3K-Akt pathway regulates cardiomyocyte size, survival, angiogenesis, and inflammation in both physiological and pathological cardiac hypertrophy. In this review, we discuss the reciprocal regulation of PI3K, Akt and mTOR in cardiomyocytes and their association with cardiac disease.
Export Options
About this article
Cite this article as:
Aoyagi Toshinori and Matsui Takashi, Phosphoinositide-3 Kinase Signaling in Cardiac Hypertrophy and Heart Failure, Current Pharmaceutical Design 2011; 17 (18) . https://dx.doi.org/10.2174/138161211796390976
DOI https://dx.doi.org/10.2174/138161211796390976 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
?Revolutionizing Cancer Treatment: Nano-Therapeutics Targeting Tumor Microenvironment?
This thematic issue explores the forefront of cancer treatment, centering on the groundbreaking potential of nano-therapeutics meticulously designed to target the tumor microenvironment. At its core, the issue aims to unravel the latest advancements in nanotechnology, showcasing innovative materials, formulations, and delivery systems that hold promise for redefining cancer therapeutics. ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Working Towards the Development of Vaccines for the Treatment and Prevention of Early Breast Cancer
Current Cancer Therapy Reviews Targeting Triglyceride Metabolism for Colorectal Cancer Prevention and Therapy
Current Drug Targets Association of Zinc and Copper Status with Cardiovascular Diseases and their Assessment Methods: A Review Study
Mini-Reviews in Medicinal Chemistry Resistance of Cancer Cells to Targeted Therapies Through the Activation of Compensating Signaling Loops
Current Signal Transduction Therapy Reduction of Sodium Intake is a Prerequisite for Preventing and Curing High Blood Pressure in Hypertensive Patients - Second Part: Guidelines
Current Hypertension Reviews Vascular Endothelin and Hypertension - From Receptors to Medicine
Current Hypertension Reviews In-hospital Falls in Older Patients: The Risk Factors and The Role of Hyponatraemia
Current Aging Science The Biology and Therapeutic Potential of the DDAH/ADMA Pathway
Current Pharmaceutical Design An Update on Clinical and Pharmacological Aspects of Drug-Eluting Stents
Cardiovascular & Hematological Disorders-Drug Targets Current Concepts Underlying Benefits of Exercise Training in Congestive Heart Failure Patients
Current Cardiology Reviews Lipid-Lowering Therapies for Atherosclerosis: Statins, Fibrates, Ezetimibe and PCSK9 Monoclonal Antibodies
Current Medicinal Chemistry Editorial [Hot Topic: Paracrine Mechanisms, Signaling and Epigenetics in Repairing Damaged Tissue]
Recent Patents on Regenerative Medicine Evidence-Based Management of Infertile Couples with Repeated Implantation Failure Following IVF
Current Women`s Health Reviews Platelet Ca2+ATPases: Identification and Regulation in Hypertension
Current Hypertension Reviews Effectors of Fatty Acid Oxidation Reduction: Promising New Anti-Ischaemic Agents
Current Pharmaceutical Design Editorial [ Hot Topic: Modifying Cardiovascular Risk Factors: Novel Cardiovascular Targets for Treatment by Noninvasive Imaging Techniques (Executive Editors: Aurelio Leone and Luigi Landini) ]
Current Pharmaceutical Design AT1 Receptor Antagonists
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Patent Selections
Recent Patents on Cardiovascular Drug Discovery Inhibition of Histone Deacetylases: A Pharmacological Approach to the Treatment of Non-Cancer Disorders
Current Topics in Medicinal Chemistry Therapeutic Exploitation of Endogenous Anti-Inflammatory Mechanisms:Old and New Leads
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry